6.50USD
31 Dec 2009
$0.00 (+0.00%)
$6.50
--
$0.00
$0.00
200
0
$7.15
$2.75
About
Overall
| Beta: | 1.10 |
| Market Cap (Mil.): | $5,579.03 |
| Shares Outstanding (Mil.): | 98.31 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| QMDAF.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 9.56 | 4.05 | 3.76 |
| EPS (TTM): | 831.33 | -- | -- |
| ROI: | 33.85 | 2.37 | 2.30 |
| ROE: | 36.82 | 3.77 | 2.82 |
UPDATE 3-Anika soars on FDA filing expectations, rival's stumble
* Expects to submit final trial data to FDA by year end
UPDATE 2-US panel rejects Q-Med, Smith/Nephew knee treatment
* Companies say will work to win approval (Adds panelist, FDA, analyst and company comment)
UPDATE 2-U.S. FDA questions studies of Q-Med's Durolane
* Shares of Q-Med rise; distributor Smith & Nephew down
UPDATE 2-US FDA staff question J&J ceramic-on-metal hip data
* Panel to decide Tuesday whether to recommend approval
U.S. FDA advisory meetings through Oct 8
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EDT/GMT.
U.S. FDA advisory meetings through Aug 19
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EDT/GMT.
UPDATE 1-NORDIC STOCKS - Factors to watch on Dec 11
HELSINKI, Dec 11 (Reuters) - The following stocks may be affected by newspaper reports and other factors on Thursday:
Founder, EQT make $502 mln offer for Q-Med
equity firm EQT and Lyftet Holding, said on Monday it was making
EUROPE-RESEARCH/ (NON-FTSEUROFIRST300)
Premiere AG Equinet Cuts to reduce from hold --------------------------------------------------------------- ------------ Q Med AB Cheuvreux Downgrades to underperform rating
TABLE-Q-MED 3-month results
Apr 29 (Reuters) - 3 months to 31 Mar 2008 Q-Med AB (Millions of Swedish crowns unless otherwise stated)





Earnings vs
Estimates